The impact of concordance with a lung cancer diagnosis pathway guideline on treatment access in patients with stage IV lung cancer

Andrew Pattison¹, Luke Jeagal², Kazuhiro Yasufuku¹, Andrew Pierre¹, Laura Donahoe¹, Jonathan Yeung¹, Gail Darling¹, Marcelo Cypel¹, Marc De Perrot¹, Tom Waddell¹, Shaf Keshavjee¹, Kasia Czarnecka-Kujawa¹,²

¹Division of Thoracic Surgery, ²Division of Respirology, Toronto General Hospital, University Health Network, University of Toronto, Ontario, Canada

Contributions: (I) Conception and design: A Pattison, K Czarnecka-Kujawa; (II) Administrative support: All authors; (III) Provision of study materials or patients: All authors; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Andrew Pattison, BSc, MBBS, FRACP. Department of Respiratory and Sleep Medicine, Sunshine Coast University Hospital, 6 Doherty Street, Birtinya, Queensland 4575, Australia. Email: andrew.pattison@health.qld.gov.au.

Background: Timely access to treatment of lung cancer is dependent on efficient and appropriate patient assessment and early referral for diagnostic workup. This study assesses the impact of Cancer Care Ontario (CCO) Lung Cancer Diagnostic Pathway Guideline (LCDPG) concordance on access to treatment of stage IV lung cancer patients referred to the Diagnostic Assessment Program (DAP) at a Canadian tertiary cancer centre.

Methods: This retrospective cohort study includes patients diagnosed with clinical stage IV lung cancer referred to the DAP at a Canadian tertiary cancer centre between November 1, 2015 and May 31, 2017. Referral concordance was determined based on CCO LCDPG. The primary outcome; time to treatment from first healthcare presentation; was compared between the concordant and discordant referrals.

Results: Two hundred patients were referred for clinical stage IV lung cancer during the study period. Of these referrals, 151 (75.5%) were assessed and referred in concordance with LCDPG. Guideline concordant referrals were associated with reduced time to treatment compared with guideline discordant referrals (55.3 vs. 108.8 days, P<0.001). Time to diagnostic procedure (32.2 vs. 86.7 days, P<0.001) and decision to treat (38.5 vs. 93.8 days, P<0.001) were also reduced with guideline concordance.

The most common reason for discordant assessment and referral was delayed or inadequate investigation of symptoms in a high risk patient (32.7% of discordant referrals).

Conclusions: Guideline concordant assessment and referral of stage IV lung cancer patients results in reduced time to diagnosis and treatment. Future research and education should focus on improving factors that delay DAP referral.

Keywords: Lung cancer; diagnostic pathway; concordance
Introduction

Lung cancer is the leading cause of cancer mortality worldwide (1). In 2016, there were 28,539 lung cancer diagnoses in Canada with 20,800 lung cancer deaths, representing a 73% mortality (2). The majority of lung cancers are diagnosed at an advanced stage which is responsible for a poor 5-year lung cancer survival (~16%) (3). In Ontario, of staged cancers (prostate, female breast, colorectal, lung and cervix), lung cancer is most likely to be diagnosed at stage III or IV (70.5% of all staged lung cancers) with stage IV cancers accounting for 49.4% of all staged lung cancers (4). Diagnosis of stage IV lung cancer is associated with poor survival and high health care utilization (5). A large proportion of Ontario patients with advanced lung cancer are hospitalized in the final 30 days of life which may reflect gaps in addressing needs of this patient population (4).

An efficient approach to the assessment and diagnosis of patients with suspected lung cancer is essential in providing prompt access to effective treatment. However, delays in this process are commonly encountered with significant heterogeneity observed across healthcare institutions (6). Such delays may be due to prolonged diagnostic workup preceding and following specialist referral (7).

In response to the need for an efficient and multidisciplinary approach to the assessment of patients with suspected lung cancer, tertiary health institutions within Ontario have established streamlined diagnostic assessment pathways (8,9). One such program was effective in reducing the time from initial suspicion of lung cancer to a diagnosis being made (8). This improvement was achieved by a multifaceted approach including a streamlined referral process and a common diagnostic algorithm.

Similarly, the University Health Network (UHN) established the Lung Rapid Assessment and Management Program (LungRAMP) in 2009. This multidisciplinary Diagnostic Assessment Program (DAP) aimed to streamline and improve access to cancer care in Ontario lung cancer patients. Between 2010 and 2017, the UHN DAP has seen a 60% increase in referrals. Overall, 2,700 patients were assessed. The majority of referred cancer patients (70%) were not surgical candidates. Advanced lung cancer has a negative impact on patient's quality of life (QOL) and survival (10) and is associated with high health care-related costs (11-13). Timely access to treatment is dependent on efficient and appropriate patient assessment and early referral for diagnostic workup. The UHN DAP has a 21-day target from receiving a patient referral to a decision to treat, which has been based on the expert consensus within Cancer Care Ontario (CCO) with a goal to have at least 50% of patients referred to any lung cancer DAP, meet this arbitrary target (14).

In November of 2015 a multidisciplinary expert panel assembled by the CCO updated the existing Lung Cancer Pathway Map, to serve as an evidence-based best practice guide to diagnostic assessment of patients with suspected and known lung cancer (15). This utility of this new Lung Cancer Diagnostic Pathway Guideline (LCDPG) in improving patient access to prompt diagnosis and treatment has not previously been assessed in clinical practice.

This study aims to assess the impact of referral concordance with a new LCDPG on access to treatment in patients with stage IV lung cancer. It also aims to assess the efficiency of a DAP in providing a diagnosis and access to treatment in patients with stage IV lung cancer. We present the following article in accordance with the STROBE reporting checklist.

Methods

The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013) and the Harmonized Tripartite Guideline for Good Clinical Practice from the International Conference on Harmonization. Ethics approval for this study was granted by the Research Ethics Board (REB) at the UHN. A single center retrospective cohort study was conducted of adult patients referred to the UHN DAP with a clinical stage IV lung cancer between November 1, 2015 and May 31, 2017. Lung cancer staging was based on the 7th edition of the TNM staging system (16). Existing medical records were retrospectively analyzed. These included province wide electronic medical records (Connecting Ontario), the UHN electronic patient record (EPR) and archived patient referral documents.

Patients were excluded if they received a diagnosis of malignancy other than lung cancer or if a definitive tissue diagnosis was not reached. Patients were also excluded if clinical stage at the time of diagnosis was not stage IV. Patients meeting the inclusion criteria were divided into two groups: (I) patients referred in concordance with the CCO LCDPG; (II) patients referred in discordance with the CCO LCDPG. Initial healthcare assessment and referral was deemed discordant according to the following categories: (I) inadequate initial investigation of suspicious symptoms as per CCO LCDPGs (15); (II) incorrect follow-
up of presumed alternative diagnosis as per CCO LCDPGs; (III) no further imaging for suspicious chest radiograph; (IV) no referral made after suspicious CT imaging as per CCO LCDPGs.

The primary study outcome was time from initial healthcare presentation to treatment initiation. Secondary outcomes were (I) time from initial healthcare presentation to diagnosis; (II) time from initial healthcare presentation to decision to treat; (III) time from referral to treatment; (IV) time from referral to diagnostic procedure; (V) time from referral to decision to treat; (VI) healthcare utilisation from referral to treatment initiation; (VII) number of diagnostic procedures required to achieve a diagnosis; and (VIII) type of diagnostic procedure used.

The initial healthcare presentation was defined as the first documented episode of the patient being assessed for signs, symptoms, or investigation findings attributable to the eventual diagnosis of lung cancer. The date of decision to treat was defined as the date on which an initial treatment modality was chosen, and/or a referral to an appropriate oncology service was made for consideration of treatment.

### Results

In the time frame of the study, 1,565 patients were referred to the UHN DAP. One thousand three hundred and sixty-five patients did not meet the inclusion criteria (Figure 1). A total of 200 patients met the inclusion criteria and were included in the final analysis. One hundred and fifty-one (75.5%) patients were assessed and referred in concordance with the CCO guidelines. Discordant assessment and referral occurred in 49 patients (24.5%). Of these discordant referrals, the reasons for discordance included inadequate initial investigation of suspicious symptoms (32.7%), incorrect follow-up of presumed alternative diagnosis (32.7%), no further imaging for suspicious chest radiograph (24.5%), and no referral to DAP despite suspicious CT imaging (30.6%). Clinical characteristics of all patients are outlined in Table 1. Patient characteristics were similar in both groups however the frequency of hemoptysis was higher in patients referred discordantly (concordant 9.3% vs. discordant 26.6%, P=0.004). The presence of pleural effusion was also more common in discordant referrals (7.3% vs. 34.7%, P=0.001). Forty patients (20%) were referred to the DAP after a tissue diagnosis was made.

The impact of referral concordance with CCO guidelines on patient treatment access from first healthcare presentation is outlined in Figure 2. Time from first presentation to treatment was significantly shorter in patients referred in concordance with CCO guidelines compared with discordant referrals (55.3±3.1 vs. 108.8±5.0 days, P<0.001). Time from first presentation to diagnostic biopsy (32.2±1.8 vs. 86.7±6.9 days, P≤0.001) and time from first presentation to decision to treat (38.4±1.9 vs. 93.8±6.5 days, P=0.001) were also significantly reduced when referrals were concordant with guidelines. Time from healthcare presentation to treatment was not significantly different between patients referred to the DAP with or without a tissue diagnosis (68.4±46.6 vs. 68.5±46.8 days, P=0.99).

The impact of referral concordance on treatment access from time of referral is displayed in Figure 3. There was no significant difference between concordant and discordant referrals in time from referral to diagnostic biopsy (18.5±1.2 vs. 22.0±2.7 days, P=0.23), decision to treat (22.9±1.3 vs. 24.4±2.6 days, P=0.59), or treatment initiation (39.7±2.6 vs. 39.4±3.3 days, P=0.95). Decision to treat was within 21 days of referral in 54.5% of all patients referred to the DAP. An average of 4.9 patient visits to hospital occurred between referral to DAP and treatment initiation. There was no significant difference observed in hospital visits between
Table 1 Patient characteristics

| Characteristics                      | All patients, N=200 [95% CI] | Concordant referrals, N=151 [95% CI] | Discordant referrals, N=49 [95% CI] | P value |
|--------------------------------------|-----------------------------|-------------------------------------|-----------------------------------|---------|
| **Symptoms**                         |                             |                                     |                                   |         |
| Cough                                | 116 (58.0%) [51.1–64.3]     | 87 (57.6%) [49.6–65.2]              | 29 (59.2%) [45.2–71.8]           | 0.88    |
| Chest pain                           | 39 (19.5%) [14.9–25.6]      | 30 (19.9%) [14.2–27.0]              | 9 (18.4%) [9.6–31.6]             | 1.00    |
| Hemoptysis                           | 27 (13.5%) [9.4–19.0]       | 14 (9.3%) [5.5–15.1]                | 13 (26.6%) [16.1–40.4]           | 0.004   |
| Dyspnea                              | 58 (29.0%) [23.1–35.5]      | 44 (29.1%) [22.5–36.9]              | 14 (28.6%) [17.8–42.5]           | 1.00    |
| Weight loss                          | 68 (34.0%) [27.8–40.8]      | 54 (35.8%) [28.6–43.7]              | 14 (28.6%) [17.8–42.5]           | 0.39    |
| Neurological symptoms                |                             |                                     |                                   |         |
| Fatigue                              | 6 (3%) [1.2–6.5]            | 6 (4.0%) [1.7–8.6]                  | 0 (0.0%) [0.0–0.9]               | 0.34    |
| MSK pain (non-chest)                 |                             |                                     |                                   |         |
| Asymptomatic                         | 34 (17%) [12.4–22.9]        | 29 (19.2%) [13.7–26.3]              | 5 (10.2%) [4.0–22.2]             | 0.19    |
| **MRC dyspnea score**                |                             |                                     |                                   |         |
| 1                                    | 117 (58.5%) [51.6–65.1]     | 92 (60.9%) [53.0–68.4]              | 25 (51.0%) [37.5–64.4]           | 0.26    |
| 2                                    | 47 (23.5%) [18.1–29.9]      | 32 (21.2%) [15.4–28.4]              | 15 (30.6%) [19.4–44.6]           | 0.18    |
| 3                                    | 20 (10%) [6.6–15.0]         | 14 (9.3%) [5.5–15.1]                | 6 (12.2%) [5.4–24.6]             | 0.59    |
| 4                                    | 15 (7.5%) [4.5–12.0]        | 12 (8.0%) [4.5–13.5]                | 3 (6.1%) [1.5–17.2]              | 1.00    |
| 5                                    | 1 (0.5%) [0.0–3.1]          | 1 (0.7%) [0.0–4.0]                  | 0 (0.0%) [0.0–0.9]               | 1.00    |
| **Comorbidities**                    |                             |                                     |                                   |         |
| None                                 | 61 (30.5%) [24.5–37.2]      | 44 (29.1%) [22.5–36.9]              | 17 (34.7%) [22.9–48.7]           | 0.48    |
| COPD                                 | 29 (14.5%) [10.2–20.1]      | 23 (15.2%) [10.3–21.9]              | 6 (12.2%) [5.4–24.6]             | 0.82    |
| Asthma                               | 4 (2%) [0.6–5.2]            | 2 (1.3%) [0.1–5.0]                  | 2 (4.1%) [0.3–14.5]              | 0.25    |
| Diabetes mellitus                    | 35 (17.5%) [12.8–23.4]      | 23 (15.2%) [10.3–21.9]              | 12 (24.5%) [14.5–38.2]           | 0.19    |
| Coronary heart disease               | 21 (10.5%) [6.9–15.6]       | 17 (11.3%) [7.1–17.4]               | 4 (8.2%) [2.7–19.7]              | 0.79    |
| Hypertension                         | 90 (45%) [38.3–51.9]        | 70 (46.4%) [38.6–54.3]              | 20 (40.8%) [28.2–54.8]           | 0.51    |
| Venous thromboembolism               | 6 (3%) [1.2–6.5]            | 4 (2.7%) [0.8–6.8]                  | 2 (4.1%) [0.3–14.5]              | 0.64    |
| Depression                           | 11 (5.5%) [3.0–9.7]         | 7 (4.6%) [2.1–9.4]                  | 4 (8.2%) [2.7–19.7]              | 0.47    |
| **Referring physician**              |                             |                                     |                                   |         |
| Emergency physician                  | 20 (10%) [6.5–15.0]         | 18 (11.9%) [7.6–18.1]               | 2 (4.1%) [0.3–14.5]              | 0.17    |
| General practitioner                 | 130 (65%) [58.2–71.3]       | 99 (65.6%) [57.7–72.7]              | 31 (63.3%) [49.2–75.4]           | 0.86    |
| Respirologist                        | 32 (16%) [11.5–21.6]        | 21 (13.9%) [9.2–20.4]               | 11 (22.4%) [12.9–36.1]           | 0.18    |
| Oncologist                           | 8 (4%) [1.9–7.8]            | 5 (3.3%) [1.2–7.7]                  | 3 (6.1%) [1.5–17.2]              | 0.41    |
| Thoracic surgeon                     | 6 (3%) [1.2–6.5]            | 5 (3.3%) [1.2–7.7]                  | 1 (2.0%) [0.0–11.7]              | 1.00    |
| Other                                | 4 (2%) [0.6–5.2]            | 3 (2.0%) [0.4–5.9]                  | 1 (2.0%) [0.0–11.7]              | 1.00    |
| Diagnosis present at time of referral| 40 (20%) [15.0–26.1]        | 34 (22.5%) [16.6–30.0]              | 6 (12.2%) [5.4–24.6]             | 0.15    |
Table 1 (continued)

| Characteristics                      | All patients, N=200 [95% CI] | Concordant referrals, N=151 [95% CI] | Discordant referrals, N=49 [95% CI] | P value |
|--------------------------------------|-----------------------------|--------------------------------------|-------------------------------------|---------|
| **Pathology type**                   |                             |                                      |                                     |         |
| NSCLC                                |                             |                                      |                                     |         |
| Adenocarcinoma                       | 116 (58.5%) [51.1–64.3]     | 86 (57.0%) [49.0–64.6]               | 30 (61.2%) [47.2–73.6]             | 0.62    |
| Squamous cell                        | 33 (16.5%) [12.0–22.3]      | 26 (17.2%) [12.0–24.1]               | 7 (14.3%) [6.8–27.0]               | 0.83    |
| Large cell                           | 16 (8%) [4.9–12.7]          | 11 (7.3%) [4.0–12.7]                 | 5 (10.2%) [4.0–22.2]               | 0.55    |
| Poorly differentiated                | 3 (1.5%) [0.3–4.5]          | 3 (2.0%) [0.4–6.0]                   | 0 (0.0%) [0.0–0.9]                 | 1.00    |
| Adenosquamous                        | 1 (0.5%) [0.0–3.1]          | 1 (0.7%) [0.0–4.0]                   | 0 (0.0%) [0.0–0.9]                 | 1.00    |
| Small cell carcinoma                 | 28 (14%) [9.8–19.5]         | 22 (14.6%) [9.8–21.1]                | 6 (12.2%) [5.4–24.6]               | 0.82    |
| Carcinoid                            | 3 (1.5%) [0.3–4.5]          | 2 (1.3%) [0.1–5.1]                   | 1 (2.0%) [0.0–11.7]                | 0.57    |
| Targetable mutation present          | 72 (36%) [29.6–42.9]        | 61 (40.4%) [30.8–45.6]               | 11 (22.4%) [12.9–36.0]             | 0.18    |
| **TNM stage (8th edition)**          |                             |                                      |                                     |         |
| M1a                                  | 66 (33%) [26.9–39.8]        | 47 (31.1%) [24.3–38.9]               | 19 (38.8%) [26.4–52.8]             | 0.38    |
| M1b                                  | 134 (67%) [60.0–73.5]       | 104 (68.9%) [60.8–76.2]              | 30 (61.2%) [46.2–74.8]             | 0.38    |
| Pleural effusion present             | 28 (14%) [9.8–19.4]         | 11 (7.3%) [4.0–12.7]                 | 17 (34.7%) [22.9–48.7]             | 0.001   |
| Initial treatment modality           |                             |                                      |                                     |         |
| None                                 | 26 (13%) [9.0–18.4]         | 22 (14.6%) [9.8–21.1]                | 4 (8.2%) [2.7–19.7]                | 0.33    |
| Chemotherapy                         | 86 (43%) [36.3–50.0]        | 69 (45.7%) [37.6–53.7]               | 17 (34.7%) [22.9–48.7]             | 0.19    |
| Radiotherapy                         | 121 (60.5%) [53.6–67.0]     | 92 (60.9%) [53.0–68.4]               | 29 (59.2%) [45.2–71.8]             | 0.87    |
| Targeted therapy                     | 43 (21.5%) [16.4–27.7]      | 30 (19.9%) [14.2–27.0]               | 13 (26.4%) [16.1–40.4]             | 0.32    |

![Figure 2](http://dx.doi.org/10.21037/jtd-20-157) Impact of referral concordance on treatment access from first healthcare presentation.
Diagnostic practices in patients referred with stage IV lung cancer are outlined in Table 2. Ninety one percent of patients referred required only one diagnostic procedure. There was no difference observed between concordant and discordant referrals in the number of diagnostic procedures required. The most common diagnostic procedure used was endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) 33.5% (95% CI, 27.3–40.3) (Figure 4). The most common location for performing diagnostic procedures was the endoscopy suite [49.0% (95% CI, 42.2–55.9)].

### Table 2 Diagnostic practices in patients with clinical stage IV lung cancer

| Variable                        | All patients, N=200 [95% CI] | Concordant referrals, N=151 [95% CI] | Discordant referrals, N=49 [95% CI] | P value |
|--------------------------------|-------------------------------|--------------------------------------|------------------------------------|---------|
| **Number or procedures required for diagnosis** |                                |                                      |                                    |         |
| 1                              | 182 (91.0%) [86.1–94.3]       | 139 (92.1%) [86.5–95.5]              | 43 (87.8%) [75.4–94.6]             | 0.39    |
| 2                              | 15 (7.5%) [4.5–12.1]          | 10 (6.6%) [3.5–11.9]                 | 5 (10.2%) [4.0–22.2]               | 0.53    |
| 3                              | 3 (1.5%) [0.3–4.5]            | 2 (1.3%) [0.1–5.0]                   | 1 (2.0%) [0.0–11.7]                | 0.57    |
| **Procedure location**         |                                |                                      |                                    |         |
| Endoscopy suite                | 98 (49.0%) [42.2–55.9]        | 75 (49.7%) [41.8–57.6]               | 23 (46.9%) [33.7–60.6]             | 0.75    |
| Interventional radiology       | 64 (32.0%) [25.9–38.8]        | 48 (31.8%) [24.9–39.6]               | 16 (32.7%) [21.2–46.7]             | 1.00    |
| Outpatient clinic              | 37 (18.5%) [13.7–24.5]        | 27 (17.9%) [12.5–24.8]               | 10 (20.4%) [11.3–33.8]             | 0.68    |
| Operating room                 | 1 (0.5%) [0.0–3.1]            | 1 (0.7%) [0.0–4.0]                   | 0 (0.0%) [0.0–8.7]                 | 1.00    |

### Discussion

Lung cancer is associated with significant morbidity and mortality with the majority of patients presenting with advanced disease (3). Prompt diagnostic assessment is essential to enable timely access to appropriate treatment modalities (14). The revised CCO LCDPG provides a framework to guide initial patient assessment and referral to a DAP for ongoing management (15). Our study confirms that concordance with this pathway in referring patients to a DAP reduces time to treatment access. Specifically, initial guideline concordant assessment and subsequent
DAP referral was associated with reduced time from initial healthcare presentation to treatment compared with discordant referrals. Time from initial healthcare presentation to diagnosis and decision to treat were also reduced with guideline concordance.

Despite the delay in accessing treatment seen in patients assessed and referred in a discordant manner, it is encouraging that the majority of patients (75.5%) were referred in concordance with the guidelines. There was no difference observed in the referral practices of General Practitioners and Specialist Physicians with regards to the CCO guidelines with similar levels of concordance seen. The specific reason for guideline discordance was varied amongst patients. The most common issue that resulted in discordant initial assessment was inadequate investigation of suspicious symptoms in a high-risk patient as defined by the CCO guidelines (see Supplementary). The most frequently encountered example of this was an unexplained cough for greater than 3 weeks that was not investigated with a chest X-ray as recommended by these guidelines. Other issues were also encountered to a similar degree, including suspicious chest radiographs or CT imaging not being further investigated or referred to the DAP as per CCO guidelines. More than one reason for discordance was also seen in some patients.

Pleural effusions and hemoptysis were more frequently observed in patients initially assessed and referred discordantly. The exact reason for this difference is not completely clear. It is possible that the delay in referral of these patients may have resulted in further disease progression leading to these findings. However, this conclusion can only be made based on the assumption that the majority of patients initially presented to a healthcare provider with similar levels of disease burden which cannot be known from this study. Alternatively, it is possible that these findings might have been originally attributed to other medical issues (i.e., bronchitis or pneumonia for patient presenting with hemoptysis) and managed accordingly, before considering a possibility of lung cancer and pursuing appropriate lung cancer DAP referral. It is important however to reinforce that prompt patient referral and diagnosis enables timely access to treatment which may potentially reduce the frequency of such disease manifestations that impact morbidity, mortality, and healthcare utilization (5). Further studies are needed to test this hypothesis.

Time from patient referral to treatment initiation was not influenced by concordance with referral guidelines. This outcome was expected as the impact of discordance with initial assessment and referral guidelines is observed in the time period prior to a DAP referral being made. As such, the delay in access to treatment is accounted for by a delay in the time from initial healthcare presentation to the time of referral. Therefore, once a referral was received by the DAP, all patients appear to have been assessed and managed by the DAP in a similar manner resulting in no significant differences in access to treatment.

Our study supports the hypothesis that a streamlined diagnostic assessment pathway is effective in providing prompt treatment access to patients with stage IV lung cancer (6,7). Overall, a decision to treat was made within 21 days from the time of referral in 54.5% of patients, satisfying the arbitrary CCO target of 50%. Adequate tissue was obtained with a single diagnostic procedure in the vast majority of patients (91.0%). Approximately half of the diagnostic procedures completed were performed in the endoscopy suite via bronchoscopy with EBUS-TBNA being the most common method used. It is important to note however that a significant number of patients were able to undergo a diagnostic procedure in an outpatient clinic setting. This included performing diagnostic thoracentesis, peripheral lymph node biopsy, soft tissue biopsy, and sputum sampling. The use of these diagnostic techniques has multiple advantages. Firstly, the risk of complication is generally lower when performing these procedures compared with endoscopic or surgical procedures which require general anesthesia or deep
sedation (17,18). Radiology guided procedures also may carry a higher risk of complication such as pneumothorax from percutaneous lung biopsy (19). Time to diagnosis can also be reduced by performing diagnostic procedures in the outpatient clinic setting at the time of the original consultation by eliminating the need for an alternative procedure that requires a subsequent hospital visit at a later date. Finally, healthcare cost can be reduced by performing procedures in the outpatient setting that require less hospital resources (20,21). Over the years our DAP has focused on streamlining the diagnostic assessment of patients with thoracic malignancy with focus on ambulatory care. With opening of the Interventional Thoracic Surgery Suite (ITSS), many of the diagnostic procedures required in patients with lung cancer performed routinely in the operating room, have been transferred to the ambulatory setting. This resulted in a reduced health care utilization and costs without compromise to diagnostic yield (20,21).

CCO guidelines recommend a 21-day target for a treatment decision to be made in all patients referred with a new diagnosis of lung cancer. These consensus guidelines were based on recommendations from the Canadian Society of Surgical Oncology and the CCO expert consensus. This decision to treat target is based primarily on evidence relating to patients with lung cancer potentially curable with either surgery or radiotherapy (22,23). As such, the predominant concern affecting wait times in these patients is the rate of tumor growth and development of metastasis which may result in the development of more advanced or incurable disease (24,25). In patients with incurable stage IV disease at the time of referral, reasons for prompt treatment may differ. For example, patients with advanced stage lung cancer are more likely to present with significant symptoms than patients with more limited disease who may be asymptomatic (25). As a result, initiation of treatment in advanced stage lung cancer may be required more urgently for symptom palliation, particularly in cases of severe or life-threatening symptoms such as hemoptysis, spinal cord compression, or superior vena cava obstruction (25). Therefore, consideration should be made as to whether the existing CCO guidelines regarding decision to treat and treatment initiation targets for lung cancer should be stratified according to stage and symptom burden. Healthcare utilization may also differ between patients with stage IV lung cancer and less advanced disease, during the initial assessment period. Our study did not directly assess this and as such further research regarding this possibility may be warranted.

The majority of patients (80%) were referred to the DAP without a tissue diagnosis. Of significance, in patients where a tissue diagnosis was made prior to referral, the time to treatment was not significantly shorter than those patients referred without a tissue diagnosis. Therefore, despite the perceived advantage of making a diagnosis prior to DAP referral, access to treatment is not improved as a result. The reasons for this are unclear. Potentially this may represent the need for such patients to still undergo further investigations to complete staging (to confirm the suspected stage IV disease) that may have not been done prior to referral. These investigations may be non-invasive such as FDG-PET imaging or may be invasive to confirm the presence of distant disease by direct tissue sampling. As such, some patients may require further invasive diagnostic procedures despite a diagnosis of lung cancer being made prior to referral. Therefore, we would suggest that patients with a suspected clinical stage IV lung cancer be referred to a DAP to both streamline assessment and limit invasive diagnostic procedures to a minimum.

While non-invasive investigations are an important component of the diagnostic and staging algorithm of lung cancer, invasive diagnostic procedures are still required in the majority of patients to guide management decisions. This requirement has traditionally exposed patients to procedures associated with significant morbidity and healthcare burden (26). However, in recent years, minimally invasive procedures are increasingly becoming the standard of care (27). EBUS-TBNA is one such example of a minimally invasive technique that enables high diagnostic accuracy while reducing complications and morbidity associated with more traditional methods such as mediastinoscopy (28-31). The development of newer targeted therapies for lung cancer has resulted in the need to perform adequate subtyping and molecular testing on diagnostic specimens. Updated molecular testing guidelines for the selection of lung cancer patients for treatment with novel targeted therapies now recommend an extensive panel of ancillary testing to be performed on diagnostic material (32). Again, minimally invasive techniques such as EBUS-TBNA have been shown to be adequate in obtaining sufficient material for this assessment (33-37). In this study, 36% of patients with stage IV lung cancer were found to have an activating mutation or molecular characteristic potentially suitable for novel targeted therapies. As a result, 21.5% of patients were commenced on targeted therapy as their initial treatment. Importantly, in those patients found to have a targetable mutation, the vast
majority (93.1%) were able to be identified with a single diagnostic procedure. It is also noteworthy that cytology specimens from minimally invasive techniques performed in the endoscopy suite and outpatient clinic were used for the majority of patients who had a targetable mutation identified.

Our study has several limitations which predominantly relate to its retrospective design. Methodology relied on existing electronic and paper medical records. Specifically, the date of initial healthcare presentation for each patient was determined from archived referrals, physician reports, and electronic records which may have not encompassed earlier presentations to a healthcare provider. Similarly, defining referral concordance was based on retrospective records. Also, although all patient visits in our institution were able to be readily analyzed, encounters with external healthcare providers in the community and in other medical facilities may not have been documented in the online systems available for review. This may have affected our data assessing the number of healthcare visits between DAP referral and treatment initiation which did not differ between discordant and concordant referrals. Despite this, we believe these factors did not significantly affect the validity of our data and primary outcome as each patient group would be equally affected by these limitations.

In conclusion, concordance with a lung cancer diagnostic assessment pathway guideline improves access to treatment in patients with stage IV lung cancer. This study also demonstrates that a lung cancer DAP is effective in providing a streamlined pathway to prompt diagnosis and treatment. The use of such guidelines and DAPs should be promoted and used to guide the assessment and referral patients with advanced lung cancer. Future research and education should focus on improving factors that delay DAP referral.

Acknowledgments

Funding: None.

Footnote

Data Sharing Statement: Available at http://dx.doi.org/10.21037/jtd-20-157

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/jtd-20-157). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The trial was conducted in accordance with the Declaration of Helsinki (as revised in 2013) and the Harmonized Tripartite Guideline for Good Clinical Practice from the International Conference on Harmonization. Ethics approval for this study was granted by the Research Ethics Board (REB) at the University Health Network (UHN) (CAPCR ID: 17-5642.2). As this was a retrospective cohort study, not involving human experiments, waiver of consent was approved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. World Health Organization. Cancer: fact sheet. World Health Organization, 2017. Available online: http://www.who.int/news-room/fact-sheets/detail/cancer
2. Canadian Cancer Society. Canadian Cancer Statistics 2016. In: Canadian Cancer Society, 2016. Available online: http://www.cancer.ca/~/media/cancer.ca/CW/cancer%20information/cancer%20101/Canadian%20cancer%20statistics/Canadian-Cancer-Statistics-2016-EN.pdf?la=en
3. Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med 2011;32:605-44.
4. Cancer Care Ontario. Ontario Cancer Statistics. In: Cancer Care Ontario, 2016.
5. Brenner KE, Krahn MD, Warren JL, et al. An international comparison of costs of end-of-life care for advanced lung cancer patients using health administrative data. Palliat Med 2015;29:918-28.
6. Jacobsen MM, Silverstein S, Quinn M, et al. Timeliness of access to lung cancer diagnosis and treatment: A scoping literature review. Lung Cancer 2017;112:156-64
7. Liberman M, Liberman D, Sampalis JS, et al. Delays to surgery in non-small cell lung cancer. Can J Surg 2006;49:31-6.
8. Lo DS, Zeldin R, Skrastins R, et al. Time to Treat: A System Redesign Focusing on Decreasing the Time from Suspicion of Lung Cancer to Diagnosis. J Thorac Oncol 2007;2:1001-6.
9. Dahele M, Ung Y, Meharchand J, et al. Integrating regional and community lung cancer services to improve patient care. Curr Oncol 2007;14:234-7.
10. Evans WK, Connor Gorber S, Spence ST, et al. Health State descriptions for Canadians: Cancers. In: Canada Statistics Canada 2005. Available online: http://publications.gc.ca/collections/Collection/Statcan/82-619-MIE/82-619-MIE2005001.pdf
11. Yabroff KR, Lund J, Kepka D, et al. Economic burden of cancer in the United States: estimates, projections, and future research. Cancer Epidemiol Biomarkers Prev 2011;20:2006-14.
12. Warren JL, Barbera L, Bremner KE, et al. End-of-life care for lung cancer patients in the United States and Ontario. J Natl Cancer Inst 2011;103:853-62.
13. Yabroff KR, Warren JL. High-cost imaging in elderly patients with stage IV cancer: challenges for research, policy, and practice. J Natl Cancer Inst 2012;104:1113-4.
14. Darling GE, Mazziak DE, Clifton JC, et al. The practice of thoracic surgery in Canada. Can J Surg 2004;47:438-45.
15. Available online: https://www.cancercareontario.ca/en/pathway-maps/lung-cancer
16. Mirsadraee S, Oswal D, Alizadeh Y, et al. The 7th lung cancer TNM classification and staging system: Review of the changes and implications. World J Radiol 2012;4:128-34.
17. Ault MJ, Rosen B, Scher J, et al. Thoracentesis outcomes: a 12-year experience. Thorax 2015;70:127-32.
18. Lochodski MP, Kozak J. Video-assisted thoracic surgery complications. Wideochir Inne Tech Maloinwazyjne 2014;9:495-500.
19. Manhine A, Charig M, Clelland C, et al. Guidelines for radiologically guided lung biopsy. Thorax 2003;58:920-36.
20. Czarnecka-Kujawa K, Rochau U, Siubert U, et al. Cost-effectiveness of mediastinal lymph node staging in non-small cell lung cancer. J Thorac Cardiovasc Surg 2017;153:1567-8.
21. McDonald CM, Pierre C, de Perrot M, et al. Efficacy and Cost of Awake Thoracoscopy and Video-Assisted Thoracoscopic Surgery in the Undiagnosed Pleural Effusion. Ann Thorac Surg 2018;106:361-7.
22. O’Rourke N, Edwards R. Lung cancer treatment waiting times and tumour growth. Clin Oncol (R Coll Radiol) 2000;12:141-4.
23. Christensen ED, Harvald T, Jendresen M, et al. The impact of delayed diagnosis of lung cancer on the stage at the time of operation. Eur J Cardiothorac Surg 1997;12:880-4.
24. Mohammed N, Kestin L, Grills I, et al. Rapid disease progression with delay in treatment of non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2011;79:466-72.
25. Ost DE, Sai-Ching J, Tanoue L, et al. Clinical and Organisational Factors in Initial Evaluation of Patients With Lung Cancer. Chest 2013;143:e121S-e141S.
26. Ost DE, Niu J, Elting L, et al. Quality Gaps and Comparative Effectiveness in Lung Cancer Staging and Diagnosis. Chest 2014;145:331-45.
27. Folch E, Costa D, Wright J, et al. Lung cancer diagnosis and staging in the minimally invasive age with increasing demands for tissue analysis. Transl Lung Cancer Res 2015;4:392-403.
28. Yasufuku K, Chiyo M, Koh E, et al. Endobronchial ultrasound guided transbronchial needle aspiration for staging of lung cancer. Lung Cancer 2005;50:347-54.
29. Navani N, Nankivell M, Lawrence DR. Lung cancer diagnosis and staging with endobronchial ultrasound-guided transbronchial needle aspiration compared with conventional approaches: an open-label, pragmatic, randomised controlled trial. Lancet Respir Med 2015;3:282-9.
30. Czarnecka-Kujawa K, Yasufuku K. The role of endobronchial ultrasound versus mediastinoscopy for non-small cell lung cancer. J Thorac Dis 2017;9:S83-S97.
31. Ernst A, Anantham D, Eberhardt R, et al. Diagnosis of Mediastinal Adenopathy—Real-Time Endobronchial Ultrasound Guided Needle Aspiration versus Mediastinoscopy. J Thorac Oncol 2008;3:577-82.
32. Lindeman NI, Cagle PT, Aisner DL, et al. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch Pathol Lab Med 2018;142:321-46.
33. Casadio C, Guarize J, Donghi S, et al. Molecular testing for targeted therapy in advanced non-small cell lung cancer: suitability of endobronchial ultrasound transbronchial needle aspiration. Am J Clin Pathol
34. Billah S, Stewart J, Staerkel G, et al. EGFR and KRAS mutations in lung carcinoma: molecular testing by using cytology specimens. Cancer Cytopathol 2011;119:111-7.

35. Lewandowska MA, Jozwicki W, Jochymski C, et al. Application of PCR methods to evaluate EGFR, KRAS and BRAF mutations in a small number of tumor cells in cytological material from lung cancer patients. Oncol Rep 2013;30:1045-52.

36. Nakajima T, Yasufuku K, Nakagawara A, et al. Multigene mutation analysis of metastatic lymph nodes in non-small cell lung cancer diagnosed by endobronchial ultrasound-guided transbronchial needle aspiration. Chest 2011;140:1319-24.

37. Lee JM, Heymann JJ, Pagan C, et al. Feasibility Of Pd-L1 Expression Testing In Non-Small Cell Lung Cancer From Ebus-Tbna Samples. Am J Respir Crit Care Med 2017;195:A2883.
Supplementary

Lung Cancer Diagnosis Pathway Map
Version 2015.11

Disclaimer
The pathway map is intended to be used for informational purposes only. The pathway map is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. Further, all pathway maps are subject to clinical judgment and actual practice patterns may not follow the proposed steps set out in the pathway map. In the situation where the reader is not a healthcare provider, the reader should always consult a healthcare provider if he/she has any questions regarding the information set out in the pathway map. The information in the pathway map does not create a physician-patient relationship between Cancer Care Ontario (CCO) and the reader.
Target Population
Patients who present with signs or symptoms suspicious of lung cancer.

Pathway Map Considerations
- Primary care providers play an important role in the cancer journey and should be informed of relevant tests and consultations.
- Ongoing care with a primary care provider is assumed to be part of the pathway. For patients who do not have a primary care provider, Health Care Connect is a government resource that helps patients find a family doctor or nurse practitioner.
- Throughout the pathway, a shared decision-making model should be implemented to enable and encourage patients to play an active role in the management of their care. For more information see Person-Centered Care Guideline and EBS #19-2 Provider-Patient Communication.
- Hyperlinks are used throughout the pathway map to provide information about relevant CCO tools, resources and guidance documents.
- The term 'health care provider', used throughout the pathway map, includes primary care providers and specialists, nurse practitioners, and emergency physicians.
- For more information on the Diagnostic Assessment Program (DAP) refer to the Organizational Standards for DAPs.

*Note. EBS #19-2 is older than 3 years and is currently listed as 'For Education and Information Purposes'. This means that the recommendations will no longer be maintained but may still be useful for academic or other information purposes.

Pathway Map Legend

- **Primary Care**
- **Supportive and End of Life Care**
- **Pathology**
- **Diagnostic Assessment Program (DAP)**
- **Surgery**
- **Radiation Oncology**
- **Medical Oncology**
- **Radiology**
- **Multidisciplinary Cancer Conference (MCC)**
- **Respirologist**

**Colour Guide**
- Intervention
- Decision or assessment point
- Patient (disease) characteristics
- Consultation with specialist
- Exit pathway
- Off-page reference
- Patient path
- Referral
- Wait time indicator time point

**Line Guide**
- Required
- Possible

Pathway Map Disclaimer
This pathway map is a resource that provides an overview of the treatment that an individual in the Ontario cancer system may receive.

The pathway map is intended to be used for informational purposes only. The pathway map is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. Further, all pathway maps are subject to clinical judgment and actual practice patterns may not follow the proposed steps set out in the pathway map. In the situation where the reader is not a healthcare provider, the reader should always consult a healthcare provider if he/she has any questions regarding the information set out in the pathway map. The information in the pathway map does not create a physician-patient relationship between Cancer Care Ontario (CCO) and the reader.

While care has been taken in the preparation of the information contained in the pathway map, such information is provided on an “as-is” basis, without any representation, warranty, or condition, whether express, or implied, statutory or otherwise, as to the information’s quality, accuracy, currency, completeness, or reliability.

CCO and the pathway map’s content providers (including the physicians who contributed to the information in the pathway map) shall have no liability, whether direct, indirect, consequential, contingent, special, or incidental, related to or arising from the information in the pathway map or its use thereof, whether based on breach of contract or tort (including negligence), and even if advised of the possibility thereof. Anyone using the information in the pathway map does so at his or her own risk, and by using such information, agrees to indemnify CCO and its content providers from any and all liability, loss, damages, costs and expenses (including legal fees and expenses) arising from such person’s use of the information in the pathway map.

This pathway map may not reflect all the available scientific research and is not intended as an exhaustive resource. CCO and its content providers assume no responsibility for omissions or incomplete information in this pathway map. It is possible that other relevant scientific findings may have been reported since completion of this pathway map. This pathway map may be superseded by an updated pathway map on the same topic.

© CCO retains all copyright, trademark and all other rights in the pathway map, including all text and graphic images. No portion of this pathway map may be used or reproduced, other than for personal use, or distributed, transmitted or “mirrored” in any form, or by any means, without the prior written permission of CCO.
The pathway map is intended to be used for informational purposes only. The pathway map is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. Further, all pathway maps are subject to clinical judgment and actual practice patterns may not follow the proposed steps set out in the pathway map. In the situation where the reader is not a healthcare provider, the reader should always consult a healthcare provider if he/she has any questions regarding the information set out in the pathway map. The information in the pathway map does not create a physician-patient relationship between Cancer Care Ontario (CCO) and the reader.

1 Refer to the American College of Chest Physicians Clinical Practice Guideline, Chest, 132, 149-160 for features of a standardized evaluation for systematic metastases and a list of paraneoplastic syndromes associated with lung cancer.

2 The following factors have been shown to increase the risk of lung cancer: current or previous smoker or second-hand exposure to tobacco smoke, history of chronic obstructive pulmonary disease, previous exposure to asbestos or other known carcinogens (e.g. radon, chromium, nickel), occupational exposure to dust or other microscopic particles (e.g. wood dust, silica), previous exposure to asbestos or other known carcinogens (e.g. radon, chromium, nickel), occupational exposure to dust or other microscopic particles (e.g. wood dust, silica), personal or family history of cancer (especially lung, head & neck), silicosis, tuberculosis.

3 These patients should be accepted by the lung DAP if the lung DAP can facilitate a diagnosis within one week.

4 An abnormal chest x-ray or an abnormal CT scan of chest suspicious of lung cancer is required with each DAP referral. A CT scan of the chest is not required for assessment of a lung DAP referral if the chest x-ray is abnormal but a CT scan—chest is required prior to assessment at a lung DAP. Patient history should be mandatory as part of the referral and include, at a minimum: comorbidities, medications, allergies major health issues and symptoms that prompted the DAP referral.

Visit to Health Care Provider

Patient presenting with any of the following signs suspicious for cancer:
- Hemoptysis (single episode)
- New finger clubbing
- Suspect lymphadenopathy (e.g. cervical, supraclavicular)
- Dysphagia
- Features of metastatic lung cancer (e.g. weight loss >5 kg, focal skeletal pain, headaches)
- Features suggestive of paraneoplastic syndromes

Or

Patient presents with any of the following unexplained symptoms for > 3 weeks (or sooner if patient has known risk factors):
- Cough
- Anorexia
- Dyspnea
- Chest and/or shoulder pain
- Abnormal chest sounds
- Hoarseness

Underlying chronic respiratory problems presenting with unexplained changes in existing symptoms

Patient presenting with any of the following:
- Stridor
- Massive hemoptysis
- New neurological signs suggestive of brain metastases or spinal cord compression including seizure

Patient presenting with any of the following:
- Persistent non-massive hemoptysis (Multiple episodes of coughing blood or blood-streaked sputum)
- Superior vena cava syndrome/obstruction

Patient presenting with abnormal imaging that reports suspicion of lung cancer (e.g. A-P ray)

Chest x-ray

Imaging as appropriate

Treatment for presenting symptoms

Lung cancer suspected?

Follow-up with family physician

Yes

R4

No

Proceed to page 4

Visit to emergency department

These are emergency situations and the patient should be seen in the ER (if not presenting there) and referred emergently to specialist

Yes

R4

Proceed to page 4

Patient history should be mandatory as part of the referral and include, at a minimum: comorbidities, medications, allergies major health issues and symptoms that prompted the DAP referral.
The pathway map is intended to be used for informational purposes only. The pathway map is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. Further, all pathway maps are subject to clinical judgment and actual practice patterns may not follow the proposed steps set out in the pathway map. In the situation where the reader is not a healthcare provider, the reader should always consult a healthcare provider if they have any questions regarding the information set out in the pathway map. The information in the pathway map does not create a physician-patient relationship between Cancer Care Ontario (CCO) and the reader.

**Lung Cancer Diagnosis Pathway Map**

**Initial Presentation and Imaging**

**Page 4 of 7**

From Page 3

**A**

- **Results**
  - High suspicion of lung cancer (based on imaging and/or clinical judgement)
  - Treatment as appropriate

**B**

- **Consolidation or unexplained (pleural effusion)**
  - Follow-up chest x-ray (EBS #24-2)
  - Results
    - Resolved
    - Follow-up with family physician
  - Non-resolving (EBS #24-2)

**C**

- **Suspected cancer**
  - Specialist
    - Thoracic surgeon, respirologist or other as appropriate
  - DAP
  - Begin staging tests at presentation to avoid delay at the staging phase. Tests may include: additional CT scan, bone scan, PET scan, MRI or CT of brain (see page 7 for more detail)

**D**

- **Normal imaging results**
  - Follow-up with family physician

**E**

- **Suspected other infectious disease process**
  - E.g. tuberculosis, atypical infections
  - Respirologist (or Internist)

**F**

- **Suspected chronic obstructive pulmonary disease (COPD) or other benign lung disease (e.g. sarcoidosis)**
  - Respirologist (or Internist)
  - Follow-up with specialist or primary care provider

**G**

- **Low suspicion of lung cancer (based on imaging and/or clinical judgement)**
  - Treatment as appropriate

**H**

- **Suspected pneumonia**
  - Treatment with antibiotics (1 cycle)
- **Suspected other infectious disease process**
  - E.g. tuberculosis, atypical infections
- **Suspected chronic obstructive pulmonary disease (COPD) or other benign lung disease (e.g. sarcoidosis)**

**I**

- **Other conditions**
  - E.g. pulmonary embolus, trauma
  - Treatment as appropriate

**J**

- **Chest x-ray**
  - Within one month after starting treatment
- **Follow-up chest x-ray**
  - Abnormal
  - Follow-up with family physician
  - Not resolved and lung cancer not suspected
    - Repeat chest x-ray
    - Sputum culture
  - Normal
  - Follow-up with family physician
  - Not resolved and suspected lung cancer
  - Repeat chest x-ray
  - Sputum culture
  - Status
    - Resolved
    - Abnormal

**K**

- **Begin staging tests at presentation to avoid delay at the staging phase. Tests may include: additional CT scan, bone scan, PET scan, MRI or CT of brain (see page 7 for more detail)**

**L**

- **New or growing solitary peripheral mass or suspicious pulmonary nodule(s) without mediastinal or hilar lymphadenopathy**
  - Central mass or clinical N1, N2, N3

**M**

- **Pleural effusion**
  - Suspected stage IV based on scans and/or patient history
  - Proceed to Page 5

**N**

- **Suspected stage IV**
  - Based on scans and/or patient history
  - Proceed to Page 6

**O**

- **Follow-up with specialist or primary care provider**
  - Treatment as appropriate

**P**

- **Follow-up with family physician**
  - Not resolved and lung cancer not suspected
  - Repeat chest x-ray
  - Sputum culture
  - Status
    - Resolved
    - Abnormal

**Q**

- **Other conditions**
  - E.g. pulmonary embolus, trauma
  - Treatment as appropriate

**R**

- **Suspected pneumonia**
  - Treatment with antibiotics (1 cycle)
- **Suspected other infectious disease process**
  - E.g. tuberculosis, atypical infections
- **Suspected chronic obstructive pulmonary disease (COPD) or other benign lung disease (e.g. sarcoidosis)**

**S**

- **Low suspicion of lung cancer (based on imaging and/or clinical judgement)**
  - Treatment as appropriate

**T**

- **Follow-up chest x-ray** (EBS #24-2)
  - Results
    - Resolved
    - Follow-up with family physician
  - Non-resolving (EBS #24-2)

**U**

- **High suspicion of lung cancer (based on imaging and/or clinical judgement)**
  - Treatment as appropriate

**V**

- **Consolidation or unexplained (pleural effusion)**
  - Follow-up chest x-ray (EBS #24-2)
  - Results
    - Resolved
    - Follow-up with family physician
  - Non-resolving (EBS #24-2)
Lung Cancer Diagnosis Pathway Map

Diagnostic Procedures

This pathway map is intended to be used for informational purposes only. The pathway map is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. Further, all pathway maps are subject to clinical judgment and actual practice patterns may not follow the proposed steps set out in the pathway map. In the situation where the reader is not a healthcare provider, the reader should always consult a healthcare provider if he/she has any questions regarding the information set out in the pathway map. The information in the pathway map does not create a physician-patient relationship between Cancer Care Ontario (CCO) and the reader.

- **New or growing solitary peripheral mass or suspicious pulmonary nodule(s) without mediastinal or hilar lymphadenopathy**
  - Bronchoscopy not possible
    - Interventional Radiology Cancer Imaging Guidelines
  - Bronchoscopy
    - Endobronchial ultrasound
      - Or
        - Mediastinoscopy
          - Or
            - Thoracic Surgery
              - Results
                - Negative but high level of clinical suspicion
                  - Follow-up by family physician, specialist or pulmonary nodule clinic
                    - Results
                      - Change in result EBS #7-20
                        - Stable
                          - Ongoing follow-up care by family physician
                        - Change in result EBS #7-20
                          - Ongoing follow-up care by family physician
  - PET/CT scan
    - EBS #7-20 and PET EBUS details
      - Needle biopsy not possible
        - Core Biopsy
          - Or
            - Fine Needle Biopsy
              - Choice is based on the expertise of the radiologist and pathologist and the ability to obtain sufficient tissue for morphological diagnosis and molecular testing. EBS #32-1.1 and Cancer Imaging Guidelines
              - Results
                - Positive for cancer or suspicious
                  - Thoracic Surgery
                    - For diagnostic purposes
                      - Cytology
                        - Cell block should be obtained
                        - And/Or
                        - Pathology
                          - Results
                            - Negative for cancer
                              - Ongoing follow-up care by family physician
                        - Negative and low level of clinical suspicion
                          - Repeat biopsy or other diagnostic testing
                            - As appropriate
                            - Ongoing follow-up care by family physician
                          - Other diagnostic testing
                          - Ongoing follow-up care by family physician
                                - Repeat biopsy or other diagnostic testing
                                  - As appropriate
                                  - Ongoing follow-up care by family physician
                      - Results
                        - Stable
                          - Ongoing follow-up care by family physician
                        - Change in result EBS #7-20
                          - Stable
                          - Ongoing follow-up care by family physician
  - Change in result EBS #7-20
    - Ongoing follow-up care by family physician
  - PET Scans Ontario Cancer Imaging Guidelines
  - Mediastinoscopy
    - If there is CT evidence of hilar and/or mediastinal lymphadenopathy
    - Or
      - May be performed by surgeon or respirologist
  - Bronchoscopy
    - Endobronchial ultrasound
      - If not previously done
        - Interventional Radiology
          - Or
            - Core Biopsy
              - Or
                - Fine Needle Biopsy
                  - Results
                    - Positive for cancer
                      - Repeat biopsy or other diagnostic testing
                        - As appropriate
                        - Ongoing follow-up care by family physician
                    - Negative and low level of clinical suspicion
                      - Repeat biopsy or other diagnostic testing
                        - As appropriate
                        - Ongoing follow-up care by family physician
                    - Negative for cancer
                      - Ongoing follow-up care by family physician
    - Core Biopsy
      - Or
        - Fine Needle Biopsy
          - Results
            - Positive for cancer
              - Repeat biopsy or other diagnostic testing
                - As appropriate
                - Ongoing follow-up care by family physician
            - Negative for cancer
              - Ongoing follow-up care by family physician
          - Results
            - Negative for cancer
              - Ongoing follow-up care by family physician
            - Stable for 2 years
              - Ongoing follow-up care by family physician
            - Change in result EBS #7-20
              - Negative and low level of clinical suspicion
                - Repeat biopsy or other diagnostic testing
                  - As appropriate
                  - Ongoing follow-up care by family physician
    - Core Biopsy
      - Or
        - Fine Needle Biopsy
          - Results
            - Positive for cancer
              - Repeat biopsy or other diagnostic testing
                - As appropriate
                - Ongoing follow-up care by family physician
            - Negative for cancer
              - Ongoing follow-up care by family physician
          - Results
            - Negative for cancer
              - Ongoing follow-up care by family physician
            - Stable for 2 years
              - Ongoing follow-up care by family physician
            - Change in result EBS #7-20
              - Negative and low level of clinical suspicion
                - Repeat biopsy or other diagnostic testing
                  - As appropriate
                  - Ongoing follow-up care by family physician

5 Depending on local resources, radial miniprobe navigational bronchoscopy with lung biopsy may be considered.
6 If the endobronchial ultrasound transbronchial needle aspiration is negative but there is a high level of suspicion of lung cancer, a mediastinoscopy should be completed.
7 Results go to ordering and referring physician and family physician
8 For more information about biomarkers, refer to the Lung Cancer Tissue Pathway
9 Follow-up as per the Fleischner guidelines. For more information see Guidelines for Management of Small Pulmonary Nodules Detected on CT Scans: A Statement from the Fleischner Society. (2005). Radiology, 237, 395-400.
Obtain sufficient tissue sample for histological and molecular diagnosis via least invasive, most accessible and most likely to upstage the patient.

Tests on pleural fluid:
- Cytology (cell block should be obtained)
- Lactate dehydrogenase
- Protein concentration
- Glucose
- Amylase
- Cell count and differential
- Culture and sensitivity

Thoracentesis
Perform procedure promptly. Can be done for diagnosis or for symptom relief. Note: If malignant cells found, this condition makes the patient inoperable.

Cancer Imaging Guidelines

Thoracic Surgery
For diagnostic purposes

Results

Positive for cancer (Stage IV)

Repeat biopsy, thoracentesis or other diagnostic testing as appropriate

Cytology Cell block should be obtained
Pathology

Suspective or negative but high level of clinical suspicion

Ongoing follow-up care by family physician

Negative and low level of clinical suspicion

Follow-up by specialist

Stable

Ongoing follow-up care by family physician

Change in result

EBS #7-20

For more information see Guidelines for Management of Small Pulmonary Nodules Detected on CT Scans: A Statement from the Fleischner Society. (2005). Radiology, 237, 395-400.

Follow-up as per the Fleischner guidelines.

7 Results go to ordering and referring physician and family physician

8 For more information about biomarkers, refer to the Lung Cancer Tissue Pathway

Pathology7,8

Cytology7

(cell block should be obtained)
Lung Cancer Diagnosis Pathway Map

The pathway map is intended to be used for informational purposes only. The pathway map is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. Further, all pathway maps are subject to clinical judgment and actual practice patterns may not follow the proposed steps set out in the pathway map. In the situation where the reader is not a healthcare provider, the reader should always consult a healthcare provider if he/she has any questions regarding the information set out in the pathway map. The information in the pathway map does not create a physician-patient relationship between Cancer Care Ontario (CCO) and the reader.

Tests to be completed if not previously done

| Clinical Stage I | PET/CT scan EBS #2-3 and PET Scans Ontario |
| Clinical Stage II | MRI brain CT if MRI is not available or contraindicated. Optional if patient is clinical stage I and asymptomatic. Cancer Imaging Guidelines |
| Clinical Stage II or IIIA | Invasive Mediastinal Staging EBS #17-4 |
| Clinical Stage IIIA-IV | Medastinoscopy Or Endobronchial Ultrasound |
| Clinical Stage IIIB | PET/CT scan EBS #17-3 PET Scans Ontario |
| Clinical Stage IV | PET/CT scan EBS #17-3 PET Scans Ontario |
| No CNS metastases | PET/CT scan EBS #17-3 PET Scans Ontario |
| CNS metastases | PET/CT scan EBS #17-3 PET Scans Ontario |
| Clinical Stage I | PET/CT scan EBS #17-3 PET Scans Ontario |
| Clinical Stage II | MRI brain CT if MRI is not available or contraindicated. Optional if patient is clinical stage I and asymptomatic. Cancer Imaging Guidelines |
| Clinical Stage IIIA-IV | Tests to be completed if not previously done |
| Clinical Stage IIIB | Bone scan If suspected metastasis, bone pain or abnormal alkaline phosphatase. Cancer Imaging Guidelines |
| Clinical Stage IVA | Bone scan If suspected metastasis, bone pain or abnormal calcium and alkaline phosphatase. Not indicated if PET/CT is negative. Cancer Imaging Guidelines |

Medical history, physical exam and blood work if not done already

Pathological Non-Small Cell Lung Cancer Diagnosis (NSCLC)
Pathological Small Cell Lung Cancer Diagnosis (SCLC)

Medical Oncologist
Radiation Oncologist

If emergency situation, symptomatic brain metastases, superior vena cava obstruction, spinal compression or stage I-III disease.